Abstract 248P
Background
Over the past decade, a growing body of literature has elucidated the involvement of zinc homeostasis in tumor growth and progression. Herein, we present a bioinformatics-based study to evaluate the prognostic potential of zinc homeostasis-related genes in ccRCC.
Methods
The Human Genome Atlas Program (TCGA) was accessed to retrieve level 3 omics data and the corresponding clinicopathological variables. Differential expression of zinc homeostasis-related genes were considered statistically significant with a |Log2(fold change)| ≥ 1.5 and a P-value ≤ .01. The prognostic potential of selected genes was assessed using multivariate Cox logistic regression analysis. LinkedOmics was used to functionally annotate significantly co-expressed genes using KEGG terminology. Enrichment of the hallmarks of cancer gene sets was tested using gene set enrichment analysis (GSEA). Tumor immune microenvironment was explored using TIMER 2.0.
Results
A total of five significant differentially expressed genes were detected, including MT1G, SLC30A2, MT1F, SLC39A1, and MT1H. The latter being the only gene with a significant prognostic profile. High MT1H expression is associated with shortened overall survival (HR: 1.534, 95% CI: 1.140-2.064, P < .0048). Multivariate Cox logistic regression identified MT1H as an independent prognostic biomarker in ccRCC (HR: 1.392, 95% CI: 1.016-1.907, P < .04). MT1H co-expressed genes annotation highlighted the involvement of mineral absorption, ribosome, oxidative phosphorylation, and proteasome pathways. GSEA illustrated several alternations in epithelial-mesenchymal transition, inflammatory response,coagulation, complement, IL-6/JAK/STAT3 signaling, glycolysis, KRAS signaling, hypoxia, E2F targets, estrogen response, INF-γ signaling, and apoptosis. No clear trends or patterns were observed in tumor immune microenvironment in response to MT1H upregulation.
Conclusions
MT1H has been identified as a potential prognostic biomarker in ccRCC. Further experimental studies are needed to confirm the observed findings and to detect the exact molecular modulators involved.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
173P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
174P - Unlocking the potential of blood-based biomarkers in pancreatic cancer for early detection and therapeutic screening
Presenter: Belinda Lee
Session: Poster Display
Resources:
Abstract
175P - Genomic evolution of peritoneal metastasis in gastric adenocarcinoma
Presenter: Lan Tu
Session: Poster Display
Resources:
Abstract
176P - Identification of novel diagnostic markers for pancreatic neuroendocrine tumors by proteomics with patient blood
Presenter: HEE SEON Kim
Session: Poster Display
Resources:
Abstract
177P - Burden of stomach cancer attributable to smoking in South Asia from 1990-2019, its projection of deaths to 2040: A benchmarking and comparative analysis
Presenter: Pranay Vaghela
Session: Poster Display
Resources:
Abstract
178P - Survival benefit of splenic hilar lymph nodes (no.10) dissection in B4 type gastric carcinoma: An IPTW propensity score analysis of large multi-institutional data
Presenter: Oh Jeong
Session: Poster Display
Resources:
Abstract
179P - The impact of pre-operative nutritional/rehabilitative assessments and support on postoperative outcomes in very elderly gastric cancer patients
Presenter: Yuki Ushimaru
Session: Poster Display
Resources:
Abstract
180P - Appraisal of surgical outcomes and oncological efficiency of intraoperative adverse events in robotic radical gastrectomy for gastric cancer
Presenter: shangguan Zhixin
Session: Poster Display
Resources:
Abstract
181P - TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study
Presenter: Zhen Huang
Session: Poster Display
Resources:
Abstract
182P - Cytoreductive surgery and chemotherapy in metastatic gastric adenocarcinoma: A population-based study
Presenter: Dana Al Zamer
Session: Poster Display
Resources:
Abstract